Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Estimated Diabetes In Japan Grows To One Per Every 5.6 Adults

This article was originally published in PharmAsia News

Executive Summary

According to a National Health and Diet Survey of 2006 conducted by Japan's Ministry of Heath, Labor and Welfare, released on April 30, the total number of diabetes patients and candidates is estimated to be 18.7 million, an increase of 15.4 percent or 2.5 million since 2002. MHLW sites a rapidly aging population, lack of exercise and high calorie diets as reasons. The estimate is based on a survey conducted in 3,600 families and utilizing blood samples of 4,296 adults. (Click here for more - Japanese language

You may also be interested in...

AstraZeneca, BMS Expand Development Of Diabetes Drug Dapagliflozin To Include Japan

TOKYO - AstraZeneca K.K., a fully owned Japanese subsidiary of AstraZeneca, has announced plans to market type 2 diabetes treatment dapagliflozin jointly with Bristol-Meyers Squibb in Japan, a company spokesman said

Takeda Introduces Vedolizumab In India Amid Signs of Gear Shift

Takeda launches blockbuster gastrointestinal drug vedolizumab in India, stepping up the tempo on the back of the local base provided by its acquisition of Shire. More expansion in the country appears to be in store for the Japanese firm.

QUOTED. 13 July 2020. Fred Colen.

The US FDA’s Circulatory System Devices advisory panel will meet on 27 October to discuss the review of the premarket approval application of Neovasc’s Reducer device, which is intended to treat angina. See what Neovasc’s CEO Fred Colen said about it here.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts